CTSO : Summary for CYTOSORBENTS COR - Yahoo Finance

U.S. Markets closed

Cytosorbents Corporation (CTSO)


NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
5.450.00 (0.00%)
At close: 4:00PM EDT
People also watch
AEMDELTPADXSONCSIGXT
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Previous Close5.45
Open5.50
Bid5.30 x 2000
Ask5.95 x 100
Day's Range5.45 - 5.55
52 Week Range3.87 - 6.90
Volume53,927
Avg. Volume58,586
Market Cap139.11M
Beta0.91
PE Ratio (TTM)-11.62
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • PR Newswire12 hours ago

    Dr. Carl H. June, Cancer Immunotherapy Pioneer, Joins CytoSorbents Scientific Advisory Board

    MONMOUTH JUNCTION, N.J., March 22, 2017 /PRNewswire/ -- CytoSorbents Corporation (CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that CAR T-cell cancer immunotherapy pioneer, Dr. Carl H. June, M.D., will join its scientific advisory board to help guide applications of the company's technology in the treatment of cancer. Dr. Carl June, Director of the Center for Cellular Immunotherapies at the University of Pennsylvania Perelman School of Medicine, stated, "Life-threatening inflammation caused by high grade cytokine release syndrome (CRS) has been observed in a wide range of cancer immunotherapies.

  • PR Newswire2 days ago

    CytoSorb® Treatment of HLH - The Parallel to Cytokine Release Syndrome in Cancer Immunotherapy

    MONMOUTH JUNCTION, N.J., March 20, 2017 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its flagship CytoSorb® blood filter to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, highlights recent cases using CytoSorb to successfully treat HLH (hemophagocytic lymphohistiocytosis) and their relevance to cytokine release syndrome (CRS) in cancer immunotherapy.

  • CytoSorbents Corp. :CTSO-US: Earnings Analysis: Q4, 2016 By the Numbers : March 16, 2017
    Capital Cube6 days ago

    CytoSorbents Corp. :CTSO-US: Earnings Analysis: Q4, 2016 By the Numbers : March 16, 2017

    Categories: Yahoo Finance Get free summary analysis CytoSorbents Corp. reports financial results for the quarter ended December 31, 2016. We analyze the earnings along side the following peers of CytoSorbents Corp. – Boston Scientific Corporation, Meridian Bioscience, Inc. and Hologic, Inc. (BSX-US, VIVO-US and HOLX-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD ... Read more (Read more...)